Long-Term Survival and Quality of Life Outcomes with Multiple Gamma Knife Radiosurgeries for Metastatic Breast Cancer to the Brain: Case Report and Review of Literature
Andrew T Roehrig, Ethan Ferrel, Robert K Fairbanks, Wayne T Lamoreaux, Alexander R MacKay, Jason A Call, John J Demakas, Aaron Wagner, Barton S Cooke, Benjamin C. Ling, Jonathan D. Carlson and Christopher M Lee
Article Type: Case Report | First Published: December 14, 2015
Metastatic disease to the brain from breast cancer can be treated with multiple modalities. Determining effective therapies for select patients with brain metastases is critical to maximizing survival and quality of life. Stereotactic radiosurgery (SRS) can be an effective option for select patients with brain metastases, and is highly targeted with rapid fall-off of radiation dose outside the treatment zone. The following case illustrates the potential use of multiple Gamma Knife Radiosurgery (...
Fascin is Expressed in Basal-Liketype Triple Negative Breast Cancer Associated with High Malignant Potential in Japanese Women
Hiromichi Tsuchiya, Akiko Sasaki, Yuko Tsunoda, Masafumi Takimoto, Terumasa Sawada, Seigo Nakamura, kentaro Iijima and Katsuji Oguchi
Article Type: Original Article | First Published: December 07, 2015
No molecular targeted drug has been developed for poor-prognostic triple-negative breast cancer (TNBC) because it has no hormone or human epidermal growth factor receptor 2 (HER2) sensitivity. In addition, TNBC has recently been sub classified into 6 types. In this study, we analyzed the expression of Fascin, an actin-binding protein associated with breast cancer, in 301 invasive breast cancer samples. Of these, 32 were identified as TNBC and were classified into the basal-like type and other no...
Palliative Management of Malignant Bowel Obstruction with Carcinomatosis
Kirti Joseph, Jaclyn Schneider and Amy A Case
Article Type: Case Report | First Published: November 27, 2015
Mr. H was a 73 year old male with a past medical history of lumbar spinal degenerative disease, pyloric stenosis repair as a child and a Hartmann procedure for a perforated diverticulitis at age 43, with colostomy reversal shortly after. In August of 2014 he was diagnosed with stage 4 colon cancer, with extensive metastases to the lung including large masses that invaded into the airways as well as a right middle and upper lobe mass compressing the superior vena cava. He underwent and assisted l...
C4.4A and Aldehyde Dehydrogenase 1 (ALDH1) May Contribute to breast Cancer not Mediated Through epithelial-Mesenchymal Transition
Natsuko Inoue, Takahiro Watanabe, Seiichi Hirota, Masahisa Ohtsuka, Hirofumi Yamamoto, Koji Morimoto, Toyomasa Katagiri and Yasuo Miyoshi
Article Type: Short Communication | First Published: November 11, 2015
C4.4A, a glycosylphosphatidyl-inositol-anchored membrane protein, plays an important role in epithelial-mesenchymal transition (EMT) affecting progression of colorectal cancer, while aldehyde dehydrogenase 1 (ALDH1) has been identified as a stem cell marker for breast cancer. Since cancer stem cells link to EMT phenotype, both molecules seem to be important for breast cancer progression mediated via EMT. In this study, associations between expressions of C4.4A or ALDH1 and vimentin, a mesenchyma...
Feasibility and Efficacy of Definitive Hypofractionated High-Dose Radiotherapy for Cutaneous Angiosarcoma of the Scalp
Emiko Shimoda, Kazuya Inoue, Nobuhide Wakai, Yoko Morimoto, Isao Asakawa, Nobumasa Fujitani, Tadashi Yoshimine, Tetsuro Tamamoto, Maiko Takeda, Kohei Ogawa, Hideo Asada and Masatoshi Hasegawa
Article Type: Original Article | First Published: November 03, 2015
Cutaneous angiosarcoma is a rare but highly aggressive vascular tumor resistant to all treatment modalities available. The aim of this study was to analyze the treatment outcomes of patients who received definitive hypofractionated high-dose radiotherapy (RT) for angiosarcoma of the scalp. Between April 2008 and December 2014, 11 patients with histologically proven cutaneous angiosarcoma of the scalp visited our Department of Radiation Oncology, because dermatologists suggested that there was no...
Cervical Cytology Screening - Is the Change of Policy Risk Free?
Emily H. Hertzberg, Nurit Ariel, Dalia Kaplan, Michal Markovitz and Zeev Blumenfeld
Article Type: Research Article | First Published: November 01, 2015
With the change in the cervical cancer screening guidelines, women younger than 21 will not be routinely screened and the screening interval is extended to three years. In spite of the well-received newly recommended guidelines on cervical cancer screening, how many patients will be excluded by the guidelines that may have otherwise benefited from the screening?. It is important to look at the trends in the screened population in order to answer this question. Our aim was to determine the effect...